Appendix 3Y
Change of Director's Interest Notice
+ See chapter 19 for defined terms.
11/3/2002
Appendix 3Y Page 1
Rule 3.19A.2
Appendix 3Y
Change of Director's Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX's property and may be made public.
Introduced 30/9/2001.
Name of entity
SIGMA PHARMACEUTICALS LIMITED
ABN
ABN 44 004 132 923
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the
director for the purposes of section 205G of the Corporations Act.
Name of Director
Brian JAMIESON
Date of last notice
16/10/2009
Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be
disclosed in this part.
Direct or indirect interest
Direct interest
Nature of indirect interest
(including registered holder)
Note: Provide details of the circumstances giving rise to the relevant
interest.
Date of change
13/11/2009
No. of securities held prior to change
177,229
Class
FPO
Number acquired
4,671
Number disposed
Value/Consideration
Note: If consideration is non-cash, provide details and estimated
valuation
$4,255.28
No. of securities held after change
181,900
Appendix 3Y
Change of Director's Interest Notice
+ See chapter 19 for defined terms.
Appendix 3Y Page 2
11/3/2002
Nature of change
Example: on-market trade, off-market trade, exercise of options, issue of
securities under dividend reinvestment plan, participation in buy-back
Shares allotted under Dividend Reinvestment
Plan
Part 2 Change of director's interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be
disclosed in this part.
Detail of contract
Nature of interest
Name of registered holder
(if issued securities)
Date of change
No. and class of securities to
which interest related prior to
change
Note: Details are only required for a contract in relation
to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration
Note: If consideration is non-cash, provide details and
an estimated valuation
Interest after change
Appendix 3Y
Change of Director's Interest Notice
+ See chapter 19 for defined terms.
11/3/2002
Appendix 3Y Page 3
Rule 3.19A.2
Appendix 3Y
Change of Director's Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX's property and may be made public.
Introduced 30/9/2001.
Name of entity
SIGMA PHARMACEUTICALS LIMITED
ABN
ABN 44 004 132 923
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the
director for the purposes of section 205G of the Corporations Act.
Name of Director
Linda Bardo NICHOLLS
Date of last notice
16/10/2009
Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be
disclosed in this part.
Direct or indirect interest
Direct interest
Nature of indirect interest
(including registered holder)
Note: Provide details of the circumstances giving rise to the relevant
interest.
Date of change
13/11/2009
No. of securities held prior to change
360,554
Class
FPO
Number acquired
11,872
Number disposed
Value/Consideration
Note: If consideration is non-cash, provide details and estimated
valuation
$10,815.39
No. of securities held after change
372,426
Appendix 3Y
Change of Director's Interest Notice
+ See chapter 19 for defined terms.
Appendix 3Y Page 4
11/3/2002
Nature of change
Example: on-market trade, off-market trade, exercise of options, issue of
securities under dividend reinvestment plan, participation in buy-back
Shares allotted under Dividend Reinvestment
Plan
Part 2 Change of director's interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be
disclosed in this part.
Detail of contract
Nature of interest
Name of registered holder
(if issued securities)
Date of change
No. and class of securities to
which interest related prior to
change
Note: Details are only required for a contract in relation
to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration
Note: If consideration is non-cash, provide details and
an estimated valuation
Interest after change
Rule 3.19A.2
Appendix 3Y
Change of Director's Interest Notice
+ See chapter 19 for defined terms.
11/3/2002
Appendix 3Y Page 5
Appendix 3Y
Change of Director's Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX's property and may be made public.
Introduced 30/9/2001.
Name of entity
SIGMA PHARMACEUTICALS LIMITED
ABN
ABN 44 004 132 923
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the
director for the purposes of section 205G of the Corporations Act.
Name of Director
William James SCOTT
Date of last notice
16/10/2009
Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be
disclosed in this part.
Direct or indirect interest
Direct interest
Nature of indirect interest
(including registered holder)
Note: Provide details of the circumstances giving rise to the relevant
interest.
Date of change
13/11/2009
No. of securities held prior to change
6,245,240
Class
FPO
Number acquired
2,610
Number disposed
Value/Consideration
Note: If consideration is non-cash, provide details and estimated
valuation
$2,377.71
No. of securities held after change
6,247,850
Appendix 3Y
Change of Director's Interest Notice
+ See chapter 19 for defined terms.
Appendix 3Y Page 6
11/3/2002
Nature of change
Example: on-market trade, off-market trade, exercise of options, issue of
securities under dividend reinvestment plan, participation in buy-back
Shares allotted under Dividend Reinvestment
Plan
Part 2 Change of director's interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be
disclosed in this part.
Detail of contract
Nature of interest
Name of registered holder
(if issued securities)
Date of change
No. and class of securities to
which interest related prior to
change
Note: Details are only required for a contract in relation
to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration
Note: If consideration is non-cash, provide details and
an estimated valuation
Interest after change
Rule 3.19A.2
Appendix 3Y
Change of Director's Interest Notice
+ See chapter 19 for defined terms.
11/3/2002
Appendix 3Y Page 7
Appendix 3Y
Change of Director's Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX's property and may be made public.
Introduced 30/9/2001.
Name of entity
SIGMA PHARMACEUTICALS LIMITED
ABN
ABN 44 004 132 923
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the
director for the purposes of section 205G of the Corporations Act.
Name of Director
David BAYES
Date of last notice
16/10/2009
Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be
disclosed in this part.
Direct or indirect interest
Direct interest
Nature of indirect interest
(including registered holder)
Note: Provide details of the circumstances giving rise to the relevant
interest.
Date of change
13/11/2009
No. of securities held prior to change
68,479
Class
FPO
Number acquired
2,255
Number disposed
Value/Consideration
Note: If consideration is non-cash, provide details and estimated
valuation
$2,054.30
No. of securities held after change
70,734
Appendix 3Y
Change of Director's Interest Notice
+ See chapter 19 for defined terms.
Appendix 3Y Page 8
11/3/2002
Nature of change
Example: on-market trade, off-market trade, exercise of options, issue of
securities under dividend reinvestment plan, participation in buy-back
Shares allotted under Dividend Reinvestment
Plan
Part 2 Change of director's interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be
disclosed in this part.
Detail of contract
Nature of interest
Name of registered holder
(if issued securities)
Date of change
No. and class of securities to
which interest related prior to
change
Note: Details are only required for a contract in relation
to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration
Note: If consideration is non-cash, provide details and
an estimated valuation
Interest after change
Appendix 3Y
Change of Director's Interest Notice
+ See chapter 19 for defined terms.
11/3/2002
Appendix 3Y Page 9
Rule 3.19A.2
Appendix 3Y
Change of Director's Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX's property and may be made public.
Introduced 30/9/2001.
Name of entity
SIGMA PHARMACEUTICALS LIMITED
ABN
ABN 44 004 132 923
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the
director for the purposes of section 205G of the Corporations Act.
Name of Director
David Gerald MANUEL
Date of last notice
26/10/2009
Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be
disclosed in this part.
Direct or indirect interest
Indirect interest
Nature of indirect interest
(including registered holder)
Note: Provide details of the circumstances giving rise to the relevant
interest.
Fully Paid Ordinary Shares held in the name
of "Manuel Super Fund" of which I am a
Trustee and Beneficiary.
Date of change
13/11/2009
No. of securities held prior to change
14,191
Class
FPO
Number acquired
467
Number disposed
Value/Consideration
Note: If consideration is non-cash, provide details and estimated
valuation
$425.44
No. of securities held after change
14,658
Appendix 3Y
Change of Director's Interest Notice
+ See chapter 19 for defined terms.
Appendix 3Y Page 10
11/3/2002
Nature of change
Example: on-market trade, off-market trade, exercise of options, issue of
securities under dividend reinvestment plan, participation in buy-back
Shares allotted under Dividend Reinvestment
Plan
Part 2 Change of director's interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be
disclosed in this part.
Detail of contract
Nature of interest
Name of registered holder
(if issued securities)
Date of change
No. and class of securities to
which interest related prior to
change
Note: Details are only required for a contract in relation
to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration
Note: If consideration is non-cash, provide details and
an estimated valuation
Interest after change
|
Print Entire Page
